TCA LA

An Israeli company providing clinical trial services for pharmaceutical, biotechnology, and medical device companies.

Angel Group Active null, Israel
Visit website ↗ LinkedIn
Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
Seed, A Round

About

TCA Clinical Research Ltd. is a privately owned Israeli company with over 20 years of experience in addressing the clinical trial needs of local and international pharmaceutical, biotechnology, medical device, and CRO companies. They offer expert and reliable services to support and conduct clinical trials from beginning to end, adhering to ICH-GCP guidelines, FDA and European regulations, and Israeli Health Authorities' regulatory procedures.

Portfolio

No portfolio companies in this dataset yet.

Q&A

What is TCA LA's primary investment focus?
TCA LA targets early-stage investment opportunities, primarily providing seed, bridge, and early Series A funding rounds. While they assess startups throughout the United States and Canada, their primary focus is on supporting California-based entrepreneurs.
What types of companies does TCA LA typically invest in?
TCA LA has a broad, generalist investment mandate, targeting companies that possess differentiated technological or operational advantages.
What support does TCA LA provide to its portfolio companies beyond financial backing?
In addition to financial backing, TCA LA provides its portfolio companies with mentorship, operational assistance, executive recruitment support, and access to an external network of over 50 domestic angel groups for deal syndication.
What is TCA LA's most recent investment?
TCA LA participated in a Seed round for LeanCon in December 2025, which raised $6 million.
Can you name a notable company in TCA LA's portfolio?
LeanCon, an AI-Powered Construction Planning and Project Automation Platform, is a notable company in TCA LA's portfolio. TCA LA invested in their $6 million Seed round in December 2025.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)